Dako revolutionizes cancer diagnostics with superfast ISH technology
(Thomson Reuters ONE) -
The wait is over for cancer patients: Dako, a global leader in tissue-based
cancer diagnostics, now introduces IQISH technology which will allow diagnosis
of cancer to go from days to hours in determining the best treatment for the
patient.
"Every second counts when you are waiting for test results that will indicate
how your cancer is treated most efficiently. We are therefore extremely proud to
introduce this new offering within our Molecular Pathology portfolio. Dako's new
IQISH technology means shorter time from biopsy to possible vital treatment for
cancer patients," says Lars Holmkvist, CEO of Dako.
HER2 IQFISH pharmDx(TM) and TOP2A IQFISH pharmDx(TM) are the first two products
available using the new fast Dako IQISH technology. The IQISH technology enables
laboratories to identify gene status with great accuracy - and now also very
fast.
Laboratories worldwide doing FISH procedures as a tool for correct
identification of patients for targeted treatments will benefit from the new
Dako IQISH technology.
"IQFISH pharmDx(TM) will provide more timely results, allowing us to incorporate
FISH analysis into our routine workflow as easily as immunohistochemistry," says
Kenneth J. Bloom, MD, FCAP, Chief Medical Officer, Clarient Diagnostic Services,
Inc, California, US.
With the new IQFISH pharmDx(TM) kits, a FISH assay can be done fast and
efficiently in only three and a half hours instead of two days as before.
"The new protocol yields very distinct signals. And with a protocol duration of
only three and a half hours it will be much easier to plan laboratory time and
handle urgent cases," says Dr. Viale, Medical Director at Istituto Europeo di
Oncologia, Milano, Italy.
As an added benefit, the buffer is non-toxic, so the teratogenic risk of
traditional formamide-containing FISH buffers can be avoided, providing a safer
and healthier work environment for the laboratory technicians.
HER2 IQFISH pharmDx(TM) and TOP2A IQFISH pharmDx(TM) have received the CE-IVD
label and are the first two IQISH products in Dako's Molecular Pathology
portfolio. The products will be available in February 2012 in Europe.
Media contact
Maia Fredtoft Søchting
Corporate Communications
Dako Denmark A/S
Tel. +45 25 46 10 83
About Dako
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics.
Hospital and research laboratories worldwide use Dako's know-how, reagents,
instruments and software to make accurate diagnoses and determine the most
effective treatment for patients suffering from cancer. Employing more than
1000 people and being present in more than 80 countries, Dako covers essentially
all of the anatomic pathology markets globally. Dako is owned by a private
equity fund EQT V.www.dako.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Dako Denmark A/S via Thomson Reuters ONE
[HUG#1582894]
Unternehmensinformation / Kurzprofil:
Datum: 06.02.2012 - 16:01 Uhr
Sprache: Deutsch
News-ID 111461
Anzahl Zeichen: 3658
contact information:
Town:
Glostrup
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 199 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Dako revolutionizes cancer diagnostics with superfast ISH technology"
steht unter der journalistisch-redaktionellen Verantwortung von
Dako Denmark A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
